Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.5% – Time to Sell?

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT)’s share price fell 6.5% during trading on Monday . The stock traded as low as $12.28 and last traded at $12.1860. 528,467 shares changed hands during trading, a decline of 54% from the average session volume of 1,161,261 shares. The stock had previously closed at $13.03.

Wall Street Analyst Weigh In

Several brokerages have recently commented on EYPT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, April 21st. HC Wainwright increased their target price on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Chardan Capital increased their target price on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Royal Bank Of Canada dropped their target price on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Citigroup increased their target price on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eyepoint Pharmaceuticals has a consensus rating of “Buy” and an average target price of $31.80.

Eyepoint Pharmaceuticals Trading Down 7.3%

The company has a market capitalization of $1.01 billion, a PE ratio of -3.45 and a beta of 1.72. The firm has a fifty day moving average of $13.31 and a two-hundred day moving average of $14.70.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.20). The company had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. On average, equities analysts expect that Eyepoint Pharmaceuticals, Inc. will post -3.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.13% of the company’s stock.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV purchased a new stake in Eyepoint Pharmaceuticals in the 1st quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after buying an additional 1,358 shares during the period. Russell Investments Group Ltd. purchased a new stake in Eyepoint Pharmaceuticals in the 3rd quarter worth approximately $76,000. Tower Research Capital LLC TRC lifted its holdings in Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after buying an additional 5,967 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after buying an additional 794 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.